Viromed Medical AG (“Viromed”; ISIN: DE000A3MQR65), a medical technology company and pioneer in cold plasma technology, today provided a strategic update on its operational orientation. The company’s focus remains on sustainable, technology-driven growth in the international MedTech market, concentrating on the development of innovative medical devices and translational research in severe respiratory diseases, particularly ventilator-associated pneumonia (VAP).
Over the past two years, Viromed has developed two novel cold plasma medical devices: ViroCAP®, an innovative cold plasma device for medical wound healing, and PulmoPlas®, a globally unique cold plasma system for applications in pneumology and respiratory tract infections. The company emphasizes the importance of the PulmoPlas® platform as the basis for future scaling across multiple medical indication areas.
In the research domain, Viromed has established a high-performance scientific consortium consisting of Hannover Medical School (MHH), the Helmholtz Centre for Infection Research (HZI) in Braunschweig, and the Leibniz Institute in Jena. This network brings together top-level expertise in infectiology, pneumology, and translational research, enabling the development of novel therapeutic approaches for respiratory tract diseases. The comprehensive publication of results by MHH and HZI is expected at the end of January 2026.
For technological development, Viromed works closely with Relyon Plasma, a subsidiary of TDK. International partnerships in Europe, Korea, and Turkey have been established to support future market entry, underscoring the global relevance of the technology. As a result of the strategic focus on research, development, and international market structures, longer innovation cycles naturally arise. Viromed deliberately refrains from communicating short-term operational interim updates, instead reporting substantial and relevant milestones in the interest of long-term, sustainable corporate development.
Viromed Medical AG’s corporate strategy is geared toward long-term value generation, with research and development programs consistently aligned with medical benefit, clinical relevance, and sustainable market potential. The company is recognized as a pioneer in pneumological research and plasma technology, and its innovation work has the potential to significantly shape future therapeutic approaches for severe respiratory infections. According to its own assessment, Viromed will play a significant role in the global fight against pathogenic germs in the coming years, particularly with PulmoPlas®.
Additionally, Viromed has successfully overcome stringent regulatory hurdles for the approval of ViroCAP® over the past 18 months, with market acceptance and demand already very high. For more information, visit the company’s website at www.viromed-medical-ag.de or view the original release on www.newmediawire.com.
